Skip to content
AnalystLens

Incyte 8-K Report, Financial Results (Feb 13, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 13, 2024
Period End
February 13, 2024
Security
INCY
In the record · 2016–202610-K1510-Q348-K107

INCY filed 15 annual reports (10-K), 34 quarterly reports (10-Q) and 107 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Oct ’17Oct ’17
  2. Material agreement8-K · Jan ’20Jan ’20
  3. Leadership change8-K · Apr ’22Apr ’22
  4. Leadership change8-K · Mar ’26Mar ’26

01—Abstract

Summary

Summary of the 8-K filed February 13, 2024. Cited figures are marked; the original filing is the authoritative source.

Incyte Corporation reported its fourth quarter and full-year 2023 financial results on February 13, 2024, as furnished in Exhibit 99.1, a press release.

For the full year 2023, total GAAP revenues were $3,695,649 thousanda ($3.7 billion), up from $3,394,635 thousand in 2022, and total net product and royalty revenues were $3.7 billion, increasing 14% year over year. Net product revenues were $3,165,168 thousand, up 15%. Jakafi net product revenues were $2,593,732 thousand for 2023 (up 8%), and Opzelura net product revenues were $337,864 thousand (up 162%).

Fourth-quarter total GAAP revenues were $1,013,341 thousandb, the first quarter the company surpassed $1 billion in total revenues, according to management. GAAP net income for the full year was $597,599 thousand, or $2.65 per diluted share, compared with $340,660 thousand, or $1.52 per diluted share, in 2022. The company issued 2024 guidance, including Jakafi net product revenues of $2,690 to $2,750 million and GAAP research and development expenses of $1,720 to $1,760 million.

Guidance excludes revenue from potential new product launches and the impact of the $25 millionc tafasitamab purchase price. Cash, cash equivalents and marketable securities totaled $3.7 billion at December 31, 2023, compared with $3.2 billion a year earlier. The release also covers pipeline updates, including a Phase 2 hidradenitis suppurativa result for ruxolitinib cream, a BLA submission for axatilimab in chronic graft-versus-host disease with approval anticipated in the second half of 2024, and FDA agreement on a path forward for once-daily ruxolitinib XR, with potential approval anticipated in approximately two years.

02—Key points

Key Highlights

  1. Total GAAP revenues of $3,695,649 thousand for FY 2023 versus $3,394,635 thousand in FY 2022; Q4 2023 total GAAP revenues of $1,013,341 thousand.
  2. GAAP diluted EPS of $2.65 for FY 2023 versus $1.52 in FY 2022; non-GAAP diluted EPS of $3.52 versus $2.78.
  3. Jakafi FY 2023 net product revenues of $2,593,732 thousand; Opzelura FY 2023 net product revenues of $337,864 thousand, up 162%.
  4. 2024 guidance: Jakafi net product revenues of $2,690 to $2,750 million; GAAP R&D expenses of $1,720 to $1,760 million; GAAP SG&A expenses of $1,210 to $1,240 million.
  5. Acquired exclusive global rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys AG for a $25 million payment in February 2024.
  6. Cash, cash equivalents and marketable securities of $3.7 billion at December 31, 2023, up from $3.2 billion a year earlier.
  7. Pipeline: ruxolitinib cream met its Phase 2 primary endpoint in hidradenitis suppurativa; axatilimab BLA submitted for chronic GVHD; FDA agreed to the path for once-daily ruxolitinib XR.

03—Questions

Frequently Asked Questions

  1. How did Incyte perform financially in 2023?

    Total GAAP revenues rose to $3,695,649 thousand from $3,394,635 thousand, and GAAP net income rose to $597,599 thousand from $340,660 thousand. GAAP diluted EPS was $2.65, compared with $1.52 in 2022.

  2. What drove revenue growth?

    Growth was primarily driven by Jakafi, with net product revenues of $2,593,732 thousand, up 8%, and Opzelura, with net product revenues of $337,864 thousand, up 162% as the launches in atopic dermatitis and vitiligo continued.

  3. What is Incyte's 2024 guidance?

    Jakafi net product revenues are guided to $2,690 to $2,750 million, and Other Hematology/Oncology net product revenues to $325 to $360 million. GAAP R&D expenses are guided to $1,720 to $1,760 million and GAAP SG&A expenses to $1,210 to $1,240 million. Guidance excludes revenue from potential new product launches and future strategic transactions.

  4. What factors affected fourth-quarter Jakafi revenue?

    Fourth-quarter Jakafi revenues were negatively affected by an increase in the number of Medicare Part D patients receiving free product and positively affected by an increase in channel inventory.

  5. What are the key pipeline catalysts mentioned?

    The release cites approval of axatilimab in chronic GVHD anticipated in the second half of 2024, Phase 2 data for ruxolitinib cream in hidradenitis suppurativa to be presented at a 2024 scientific meeting, clinical proof-of-concept for zilurgisertib by mid-2024, and potential approval of once-daily ruxolitinib XR in approximately two years.

04—Continue

← View all 8-K filings